{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:04:32Z","timestamp":1793376272944,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Many indications in dermatology can be effectively managed with topical antibiotics, including acne vulgaris, wound infections, secondarily infected dermatitis, and impetigo. Dermatologists must be familiar with the wide spectrum of topical antibiotics available, including indications, mechanisms of action, adverse events, and spectra of activity. Dermatologists must also keep antibiotic resistance in mind when utilizing these medications. Due to the widespread use of topical antibiotics and their importance in dermatology, a literature review was performed using a systematic search of PubMed and Google Scholar with the terms topical antibiotics, skin infections, dermatology, antimicrobials, and inflammatory dermatoses to identify English-language articles published between 1965\u20132022 from any country. Relevant publications were manually reviewed for additional content. The following literature review will summarize the common topical antibiotics used in dermatology.<\/jats:p>","DOI":"10.3390\/antibiotics12020188","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:36:55Z","timestamp":1673933815000},"page":"188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Topical Antibiotic Treatment in Dermatology"],"prefix":"10.3390","volume":"12","author":[{"given":"Matthew","family":"Dallo","sequence":"first","affiliation":[{"name":"Department of Dermatology, The University of Texas Health Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavina","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas Health Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, The University of Texas Health Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1529-8019.2008.00190.x","article-title":"Local antibiotics in dermatology","volume":"21","author":"Gelmetti","year":"2008","journal-title":"Dermatol. Ther."},{"key":"ref_3","first-page":"153","article-title":"Amikacin gel administration in the treatment of peristomal dermatitis","volume":"24","author":"Nicolai","year":"1998","journal-title":"Drugs Exp. Clin. Res."},{"key":"ref_4","first-page":"964","article-title":"Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application","volume":"14","author":"Schulte","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_5","first-page":"175","article-title":"L\u2019acido azelaico nella terapia dell\u2019acne [Azelaic acid in the treatment of acne]","volume":"124","author":"Passi","year":"1989","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-4632.2005.02769.x","article-title":"Azelaic acid (15% gel) in the treatment of acne rosacea","volume":"46","author":"Gupta","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1346-8138.15739","article-title":"Broad spectrum in vitro microbicidal activity of benzoyl peroxide against microorganisms related to cutaneous diseases","volume":"48","author":"Okamoto","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_8","unstructured":"Matin, T., and Goodman, M.B. (2022). Benzoyl Peroxide, StatPearls."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijd.IJD_99_18","article-title":"Topical Antibacterials in Dermatology","volume":"66","author":"Bandyopadhyay","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bcp.2016.12.001","article-title":"Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications","volume":"133","author":"Spizek","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1517\/14656566.8.15.2625","article-title":"Topical clindamycin in the management of acne vulgaris","volume":"8","author":"Guay","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","first-page":"71","article-title":"Topical clindamycin versus oral tetracycline and placebo in acne vulgaris","volume":"43","author":"Braathen","year":"1984","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archderm.1976.01630260010003","article-title":"Topically applied antibiotics in acne vulgaris: Clinical Response and Suppression Corynebacterium acnes in Open Comedones","volume":"112","author":"Resh","year":"1976","journal-title":"Arch. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2340\/00015555-70534537","article-title":"A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris","volume":"70","author":"Cunliffe","year":"1990","journal-title":"Acta Derm. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American Clinical Management Guidelines for hidradenitis suppurativa: A publication from the United States and Canadian hidradenitis suppurativa foundations","volume":"81","author":"Alikhan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of Hidradenitis Suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e01810-19","DOI":"10.1128\/AAC.01810-19","article-title":"Transferable Multidrug-Resistance Plasmid Carrying a Novel Macrolide-Clindamycin Resistance Gene, erm(50), in Cutibacterium acnes","volume":"64","author":"Aoki","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1835603","DOI":"10.1155\/2022\/1835603","article-title":"Inducible Clindamycin-Resistant Staphylococcus aureus Strains in Africa: A Systematic Review","volume":"2022","author":"Assefa","year":"2022","journal-title":"Int. J. Microbiol."},{"key":"ref_21","unstructured":"Murphy, P.B., Bistas, K.G., and Le, J.K. (2022). Clindamycin-StatPearls, StatPearls Publishing."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archderm.1981.01650030032015","article-title":"Pseudomembranous colitis after topical application of clindamycin","volume":"117","author":"Milstone","year":"1981","journal-title":"Arch. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archderm.1986.01660170113031","article-title":"Pseudomembranous colitis caused by topical clindamycin phosphate","volume":"122","author":"Parry","year":"1986","journal-title":"Arch. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/15569527.2021.2024565","article-title":"Dapsone for the treatment of acne vulgaris: Do the risks outweigh the benefits?","volume":"41","author":"Temiz","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_25","first-page":"553","article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: First of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Jarratt","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_26","first-page":"962","article-title":"Efficacy and safety of once-daily dapsone gel 7.5% for treatment of adolescents and adults with acne vulgaris: Second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Eichenfield","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMc1408272","article-title":"Methemoglobinemia as a complication of topical dapsone","volume":"372","author":"Swartzentruber","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"30257","DOI":"10.1074\/jbc.M112.378521","article-title":"Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus","volume":"287","author":"Koripella","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2133.1998.1390s3037.x","article-title":"Fusidic acid in dermatology","volume":"139","author":"Wilkinson","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"a025437","DOI":"10.1101\/cshperspect.a025437","article-title":"Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections","volume":"6","author":"Fernandes","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_31","first-page":"453","article-title":"Fusidic acid in skin infections and infected atopic eczema","volume":"149","author":"Bonamonte","year":"2014","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1684\/ejd.2010.0833","article-title":"Fusidic acid in dermatology: An updated review","volume":"20","author":"Simonsen","year":"2010","journal-title":"Eur. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Buechler, C.R., and Daveluy, S.D. (2021). A Comprehensive Guide to Hidradenitis Suppurative-Topical Therapeutics, Elsevier.","DOI":"10.1016\/B978-0-323-77724-7.00015-2"},{"key":"ref_34","unstructured":"Aronson, J.K. (2016). Fusidic Acid. The International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier. [16th ed.]."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"(1967). Gentamicin. Br. Med. J., 1, 158\u2013159.","DOI":"10.1136\/bmj.1.5533.158"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjd.19710","article-title":"Guidelines for the management of hidradenitis suppurativa: Recommendations supported by the Centre of Evidence of the French Society of Dermatology","volume":"184","author":"Bertolotti","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00128071-200001030-00007","article-title":"Topical Metronidazole","volume":"1","author":"McClellan","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","article-title":"Topical metronidazole therapy for rosacea","volume":"123","author":"Bleicher","year":"1987","journal-title":"Arch. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.1983.tb03972.x","article-title":"Treatment of rosacea with 1% metronidazole cream. A double-blind study","volume":"108","author":"Nielsen","year":"1983","journal-title":"Br. J. Dermatol."},{"key":"ref_40","unstructured":"(2023, January 02). Highlights of Prescribing Information ZILXI. ZILXI (Minocycline) Topical Foam, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213690s000lbl.pdf."},{"key":"ref_41","unstructured":"(2023, January 02). Highlights of Prescribing Information AMZEEQ. AMZEEQ (Minocycline) Topical Foam, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212379s000lbl.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","article-title":"Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials","volume":"82","author":"Gold","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40257-020-00523-1","article-title":"Topical Minocycline Foam 4%: A Review in Acne Vulgaris","volume":"21","author":"Paik","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_44","first-page":"14","article-title":"Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris","volume":"13","author":"Kircik","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_45","unstructured":"(2023, January 09). Information for Patients. Discover AMZEEQ|AMZEEQ\u00ae (Minocycline) Topical Foam, 4%. Available online: https:\/\/www.amzeeq.com\/about-amzeeq."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10529-019-02670-w","article-title":"Mupirocin: Applications and production","volume":"41","author":"Tucaliuc","year":"2019","journal-title":"Biotechnol. Lett."},{"key":"ref_47","unstructured":"Food and Drug Administration (2023, January 02). Bactroban Cream, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/605495","article-title":"Mupirocin Resistance","volume":"49","author":"Patel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamadermatol.2022.3168","article-title":"Antibiotic Stewardship in Dermatology-Reducing the Risk of Prolonged Antimicrobial Resistance in Skin","volume":"158","author":"Margaret","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_50","unstructured":"Nguyen, R., Khanna, N.R., Safadi, A.O., and Sun, Y. (2022). Bacitracin Topical, StatPearls."},{"key":"ref_51","unstructured":"Shatri, G., and Tadi, P. (2022). Polymyxin, StatPearls."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1751-7915.2008.00063.x","article-title":"Mechanism of action of and resistance to quinolones","volume":"2","author":"Madurga","year":"2009","journal-title":"Microb. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jamadermatol.2018.1103","article-title":"Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients with Impetigo: A Randomized Clinical Trial","volume":"154","author":"Rosen","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_54","unstructured":"(2023, January 01). Highlights of Prescribing Information XEPI (Ozenoxacin) Topical Cream, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208945lbl.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: Potent drugs for resistant bugs\u2014Mode of action and resistance","volume":"7","author":"Paukner","year":"2016","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"ref_56","first-page":"1537","article-title":"Retapamulin (Altabax) 1% Topical Ointment for the Treatment of Impetigo","volume":"76","author":"Coutinho","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/INF.0000000000003123","article-title":"Retapamulin activity against pediatric strains of mupirocin-resistant methicillin-resistant Staphylococcus aureus","volume":"40","author":"Patel","year":"2021","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:08:08Z","timestamp":1760119688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/2\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["antibiotics12020188"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12020188","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]}}}